Researchers at the University of Southampton have uncovered a hidden culprit in blood cancer, a unique sugar molecule that disguises aggressive lymphoma cells and renders them resistant to conventional treatments. This breakthrough reported by News Medical Life Sciences, identification of “Mann-type DLBCL,” a previously unrecognized subtype of diffuse large B-cell lymphoma, promises to transform how doctors diagnose and treat this high-risk cancer.
A Cancer in Disguise
Lymphoma is a blood cancer affecting lymphocytes, white blood cells that normally defend the body against infection. Diffuse large B-cell lymphoma (DLBCL) specifically targets B cells, which are critical immune fighters. While DLBCL encompasses numerous subtypes, this new Mann-type variant represents a particularly aggressive form—one that has evaded proper classification and, consequently, optimal treatment.
An international research team spanning the University of Southampton, Canada, and the United States analyzed data from 595 DLBCL patients using datasets from the BC Cancer Agency and the National Cancer Institute. Their investigation revealed a striking discovery: approximately one-third of all DLBCL cases carry a specific sugar called mannose on their B-cell receptors, consistently defining this new subtype.
The Sugar That Shields Cancer
Mannose typically appears on infectious agents like viruses, rarely surfacing on normal human cells. Yet Mann-type DLBCL cells coat themselves with this unusual carbohydrate, which paradoxically enhances their survival and accelerates growth. The sugar essentially camouflages the cancer from immune surveillance and, more critically, from conventional anti-cancer drugs. This protective coating drives treatment resistance and produces unusually aggressive disease with significantly worse patient outcomes compared to other DLBCL subtypes.
“It is highly unusual to see these kinds of carbohydrates play such a defining role in cancer biology,” noted Professor Max Crispin, Director of the University of Southampton’s Institute for Life Sciences. “Finding mannose structures driving tumour growth is remarkable and a powerful example of how interdisciplinary science can transform our understanding of disease.”
Clinical Implications
Lead researcher Professor Francesco Forconi emphasized the therapeutic importance of this discovery:
“Patients with this new subtype have a high-risk cancer that cannot respond well to conventional therapies, so identifying this as a distinct group is very important to their treatment programme.”
This classification matters profoundly. Previously, physicians could not distinguish Mann-type DLBCL from other DLBCL subtypes, leading to inappropriate treatment protocols and preventable treatment failures. Now, using conventional laboratory tests, clinicians can reliably identify this specific subtype, enabling more accurate prognostication and informed treatment planning.
Path Forward
The research opens unprecedented therapeutic opportunities. Understanding that mannose actively promotes cancer cell survival creates specific vulnerability points for intervention. Scientists can now develop targeted therapies designed to neutralize mannose’s protective effects or exploit the sugar-mediated survival pathway.
“Understanding the type of cancers we fight is a crucial part of battling the disease and opens the door to developing new and improved therapies,” Forconi stated.
For the approximately one-third of DLBCL patients with the Mann-type variant, this breakthrough represents genuine hope—the prospect of escaping treatment resistance through precision medicine tailored to their cancer’s unique molecular signature. As researchers work to develop these targeted interventions, countless patients stand to benefit from science that finally sees their cancer clearly.
